Efficacy of single intravenous injection of peramivir against influenza B virus infection in ferrets and cynomolgus macaques

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 11, 2011, Pages 4961-4970

  Kitano, Mitsutaka ^a,b   Itoh, Yasushi ^a   Kodama, Makoto ^b   Ishigaki, Hirohito ^a   Nakayama, Misako ^a   Ishida, Hideaki ^a   Baba, Kaoru ^b   Noda, Takahiro ^b   Sato, Kenji ^b   Nihashi, Yoichiro ^b   Kanazu, Takushi ^b   Yoshida, Ryu ^b   Torii, Ryuzo ^a   Sato, Akihiko ^b   Ogasawara, Kazumasa ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; PERAMIVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; FERRET; INFLUENZA B; INFLUENZA VIRUS B; MACACA; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CYCLOPENTANES; FERRETS; GUANIDINES; INFLUENZA B VIRUS; INJECTIONS, INTRAVENOUS; MACACA; ORTHOMYXOVIRIDAE INFECTIONS;

EID: 80054709261     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00412-11     Document Type: Article

References (35)

1. Air, G. M., et al. 1990. Antigenic, sequence, and crystal variation in influenza B neuraminidase. Virology 177:578-587. (Pubitemid 20235179)
2. Babu, Y. S., et al. 2000. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J. Med. Chem. 43:3482-3486.
3. Bantia, S., et al. 2001. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob. Agents Chemother. 45:1162-1167. (Pubitemid 32230997)
4. Birnkrant, D., and E. Cox. 2009. The Emergency Use Authorization of VOL. 55, 2011 PERAMIVIR AGAINST INFLUENZA B VIRUS INFECTION 4969 peramivir for treatment of 2009 H1N1 influenza. N. Engl. J. Med. 361:2204-2207.
5. Boivin, G., and N. Goyette. 2002. Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors. Antiviral Res. 54:143-147. (Pubitemid 34327680)
6. Boltz, D. A., et al. 2008. Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice. Antiviral Res. 80:150-157.
7. Chand, P., et al. 1997. Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design. J. Med. Chem. 40:4030-4052. (Pubitemid 28008399)
8. Collins, P. J., et al. 2008. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 453:1258-1261. (Pubitemid 351913590)
9. Govorkova, E. A., et al. 2007. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob. Agents Chemother. 51:1414-1424. (Pubitemid 46586824)
10. Govorkova, E. A., I. A. Leneva, O. G. Goloubeva, K. Bush, and R. G. Webster. 2001. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob. Agents Chemother. 45:2723-2732. (Pubitemid 32906663)
11. Gubareva, L. V., M. N. Matrosovich, M. K. Brenner, R. C. Bethell, and R. G. Webster. 1998. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178:1257-1262.
12. Hatakeyama, S., et al. 2007. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 297:1435-1442. (Pubitemid 46556469)
13. Hayden, F. G., et al. 1999. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 282:1240-1246. (Pubitemid 29468495)
14. Herlocher, M. L., et al. 2001. Ferrets as a transmission model for influenza: sequence changes in HA1 of type A (H3N2) virus. J. Infect. Dis. 184:542-546. (Pubitemid 32783543)
15. Hurt, A. C., et al. 2006. Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient. Antimicrob. Agents Chemother. 50:1872-1874.
16. Hurt, A. C., et al. 2010. Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model. J. Virol. 84:9427-9438.
17. Itoh, Y., et al. 2009. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460:1021-1025.
18. Itoh, Y., et al. 2010. Subcutaneous inoculation of a whole virus particle vaccine prepared from a non-pathogenic virus library induces protective immunity against H7N7 highly pathogenic avian influenza virus in cynomolgus macaques. Vaccine 28:780-789.
19. Jackson, S., et al. 2009. Reassortment between avian H5N1 and human H3N2 influenza viruses in ferrets: a public health risk assessment. J. Virol. 83:8131-8140.
20. Kawai, N., H. Ikematsu, N. Iwaki, N. Hirotsu, and S. Kashiwagi. 2006. Prevalence of influenza B during the 2004-2005 season in Japan. Clin. Infect. Dis. 43:1226-1228. (Pubitemid 44632817)
21. Kawai, N., et al. 2007. Longer virus shedding in influenza B than in influenza A among outpatients treated with oseltamivir. J. Infect. 55:267-272. (Pubitemid 47248483)
22. Kawai, N., et al. 2006. A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons. Clin. Infect. Dis. 43:439-444. (Pubitemid 44157151)
23. Kitano, M., et al. 2010. Establishment of a cynomolgus macaque model of influenza B virus infection. Virology 407:178-184.
24. Kohno, S., H. Kida, M. Mizuguchi, and J. Shimada. 2010. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob. Agents Chemother. 54:4568-4574.
25. Kubo, S., T. Tomozawa, M. Kakuta, A. Tokumitsu, and M. Yamashita. 2010. Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration. Antimicrob. Agents Chemother. 54:1256-1264.
26. Lee, N., et al. 2009. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J. Infect. Dis. 200:492-500.
27. Matrosovich, M., T. Matrossovich, J. Carr, N. A. Roberts, and H.-D. Klenk. 2003. Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J. Virol. 77:8418-8425. (Pubitemid 36871470)
28. Munster, V. J., et al. 2009. Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. Science 325:481-483.
29. Newland, J. G., et al. 2003. Encephalitis associated with influenza B virus infection in 2 children and a review of the literature. Clin. Infect. Dis. 36:e87-e95.
30. Peltola, V., T. Ziegler, and O. Ruuskanen. 2003. Influenza A and B virus infections in children. Clin. Infect. Dis. 36:299-305. (Pubitemid 36169665)
31. Pinto, L. H., and R. A. Lamb. 2006. The M2 proton channels of influenza A and B viruses. J. Biol. Chem. 281:8997-9000. (Pubitemid 43864610)
32. Sugaya, N., et al. 2007. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin. Infect. Dis. 44:197-202. (Pubitemid 46079980)
33. Tashiro, M., et al. 2009. Surveillance for neuraminidase-inhibitor- resistant influenza viruses in Japan, 1996-2007. Antivir. Ther. 14:751-761.
34. World Health Organization. 2010. Influenza activity in the world. Global alert and response. World Health Organization, Geneva, Switzerland. http: //www.who.int/csr/disease/influenza/update/en/index.html.
35. Yun, N. E., et al. 2008. Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1). Virology 374:198-209.